The most frequently asked question in 2018: InflammAging
Dr. Wolfgang Brysch
For this blog entry, we’ve been thinking: Is there a question that has been asked most frequently this year? And what does the answer say about our work at MetrioPharm?
The most frequently asked question clearly was: “Is MetrioPharm working on InflammAging?”
MetrioPharm at the ECTRIMS Conference in Berlin
The ECTRIMS Conference is the largest international conference on the treatment of multiple sclerosis. Dr. Sara Schumann and Dr. Astrid Kaiser presented preclinical data for MetrioPharm.
Photo: © Astrid Kaiser
In October you attended the ECTRIMS conference for MetrioPharm. What was your impression?
Dr. Sara Schumann: The conference is immense. This year there were more than 9000 participants who met in Berlin. One can say that this international conference is the most important forum for researchers and clinicians on multiple sclerosis (MS).
Dr. Astrid Kaiser: Many MS therapies already available today were presented. Of course, we can learn a lot from these post-marketing studies as they clearly show the advantages and disadvantages of currently available drugs.
What kind of company is MetrioPharm?
Dr. Wolfgang Brysch
We have spent this summer on the road. While the scientific team oversaw the progress of our Phase II clinical trial, our Business Development and Investor Relations staff introduced MetrioPharm AG to many different people: potential development partners, medical scientists, financial analysts, healthcare experts and investors.
A background interview on MetrioPharm’s Phase II study
Dr. Petra Schulz, Senior Manager Drug Development at MetrioPharm spoke to us about the ongoing Phase II clinical trial and the details of the current press release
Photo: © F. Edler
MetrioPharm’s lead compound MP1032 entered Phase II clinical testing in early March. How has the study gone so far?
Dr. Petra Schulz: The most important goal of a large Phase II study continues to be to test the safety of the drug, i.e. whether the patients tolerate it well. So far, nobody has had to discontinue the study after taking MP1032, which is a good signal. The other important objectives – proof of efficacy and the search for the optimal dosage – are still unknown, because at the moment the study is blinded.
This week there was a...
MetrioPharm presents mode of action of MP1032 at a scientific conference
The 19th Meeting of the Society for Free Radical Research International 2018 in Lisbon
What is the most important step in the development of a new drug? The successful completion of preclinical trials, the first clinical study in humans or the proof of efficacy in patients? All these steps are a precondition for approval; they show that the drug works...
Interview with the MetrioPharm Founders
The founders from left to right: Dr.Wolfgang Brysch, Rudolf Stäger and Ekkehard Brysch, Foto: © Eva Brysch
In spring 2018, we met the three founders of MetrioPharm AG in Zurich for an interview. We talked about the right intuition for molecules with potential, about the ongoing clinical trial and MetrioPharm’s plans for the future
In 2007, the three of you founded MetrioPharm AG together. How did this happen?
What we can learn from our competitors
A recent study investigates the correlation between chronic inflammation and Alzheimer’s disease.
Foto: © Fotolia
In our last blog entry, our CEO Dr. Wolfgang Brysch replied to the question: “Does MetrioPharm have competition? You can find the full article here. In this article we take a closer look at a drug that has already been tested.
If a patient suffers from an autoimmune disease, for example psoriasis, his physician ...
Does MetrioPharm have competition?
Dr. Wolfgang Brysch
When I get this question – which happens a lot – I usually answer: ‘Yes, MetrioPharm has competition. And then again, no, MetrioPharm has no competition.’
On the one hand, there are drugs for chronic inflammatory diseases already approved today, and our MP1032 will be competing with them...
A life sign from the blog editors
Almost done – last work on the MetrioPharm annual report
Photo: © Eva Brysch, 2018
You may have noticed it – for a while it was quiet on our blog. The reason is not that we have lost interest in blogging, the reason is June 20, 2018.
On June 20, the 12th Annual General Meeting of MetrioPharm AG will take place in Kloten; on that day a stack of freshly printed annual reports will be ready to inform new and old shareholders about...
All relevant information on the start of the Phase II trial
On March 7, 2018, MetrioPharm announced “First Patient First Dose” for its ongoing Phase II clinical trial, a “multi-center, double-blind, placebo-controlled, clinical trial in the indication psoriasis.”
For our blog, we have collected the keywords from this press release and explain what they mean in concrete terms for MetrioPharm and our ongoing trial.
Phase II trial
A medical substance ...